Biosergen
Biosergen publishes interim report for third quarter 2023
REG
Summary of the Interim Report for Q3 2023
| 2023 | 2022 | 2023 | 2022 | 2022 | |
| TSEK | July-Sep | July-Sep | Jan-Sept | Jan-Sep | Jan-Dec |
| Profit/loss | |||||
| Other income | 292 | 493 | 8.063 | 3.219 | 5.183 |
| Profit/loss before depreciation (EBITDA | -7.537 | -14.515 | -20.604 | -27.496 | -34.129 |
| Operating profit/loss befor net financials | -7.537 | -14.515 | -20.604 | -27.496 | -34.129 |
| Net financials | 27 | 16 | 36 | 22 | 81 |
| Netprofit/loss for the period | -7.510 | -14.499 | -20.568 | -27.474 | -34.048 |
| Earnings per share (SEK) | -0,15 | -0,51 | -0,48 | -0,97 | -1,09 |
Highlights during Q3 2023
- September 25, Biosergen and Alkem Laboratories Ltd collaborates to develop anti-infective for severe fungal infections.
- August 28, Warrants series TO2 were exercised to approximately 96.1 percent and Biosergen AB receives approximately SEK 5.5 million.
- August 16, Biosergen Receives Full Subscription Guarantees for Warrant Exercise from Largest Shareholders and Executive Management.
- August 7, Biosergen Announces Abstract Accepted for Presentation at the 11th Congress on Trends in Medical Mycology (TIMM-11).
Highlights after the period
- Abstract presented at the 11th Trends in Medical Mycology publicly available
The Financial report can be found on our website: https://biosergen.net/investors/filings
| Datum | 2023-11-30, kl 12:04 |
| Källa | Cision |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!